Baltic Horizon Fund consolidated un-audited financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
84
Baltic Horizon Fund consolidated un-audited financial results for Q4 2016.

Baltic Horizon Fund publishes consolidated un-audited financial results for Q4 2016.

As at 31 December 2016 the GAV of the Fund increased to EUR 154.9 million (EUR 133.7 million as at 30 September 2016). The increase is mainly related to the acquisition of Pirita shopping centre and the increase in cash as a result of the second public offering.

As of 31 December 2016, the Fund NAV was EUR 76.8 million, compared to EUR 57.2 million as at 30 September 2016. The increase in NAV is mainly related to the new capital raised during the second public offering (approx. EUR 19.5 million net of subscription fees) and the performance of the Fund.

During Q4 2016, the Fund recorded a net profit of EUR 1.2 million (EUR 3.2 million during Q4 2015) which had a positive effect on the Fund NAV. The net result was positively affected by the quarter-end revaluation of Domus Pro and the operational performance of the properties. Since the valuation of the properties took place in September, the Fund did not commission new valuations for the entire portfolio as of the year-end. The next valuations are planned to be conducted in June 2017. Net profit in Q4 2015 was higher because of property valuation gains.

In Q4 2016, the net rental operating income (NOI) earned by the Group amounted to EUR 2.3 million (EUR 7.2 million during twelve months ended December 2016) and was higher than in Q4 2015 when the Group earned EUR 1.6 million (EUR 5.3 million during twelve months ended December 2015). Compared to 2015, the increase in NOI is mainly related to rental income earned by the new acquisitions G4S Headquarters, Upmalas Biroji and Pirita shopping centre.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Euro ‘000 Q4 2016 Q4 2015 2016 2015
         
Rental income 2,540 1,748 7,874 6,073
Expenses reimbursement revenue 784 594 2,594 2,062
Cost of rental activities (1,014) (792) (3,315) (2,796)
Net rental income 2,310 1,550 7,153 5,339
         
Administrative expenses (728) (363) (2,190) (984)
Other operating income / (expenses) 2 1 97 267
Net loss on disposal of investment property - - - (10)
Valuation gains / (loss) on investment properties 201 2,886 2,562 2,886
Valuation gains / (loss) on investment property under construction 175 - 175 -
Operating profit 1,960 4,074 7,797 7,498
         
Financial income 3 3 14 17
Financial expenses (413) (286) (1,253) (1,100)
Net financing costs (410) (283) (1,239) (1,083)
         
Profit before tax 1,550 3,791 6,558 6,415
Income tax charge (370) (602) (798) (890)
Profit for the period 1,180 3,189 5,760 5,525
         
Other comprehensive income to be reclassified to profit or loss in subsequent periods
Net gains (losses) on cash flow hedges (48) (37) (113) (23)
Income tax relating to net gains (losses) on cash flow hedges 19 7 18 18
Other comprehensive income/ (expense), net of tax, to be reclassified to profit or loss in subsequent periods (29) (30) (95) (5)
         
Total comprehensive income/ (expense) for the period, net of tax 1,151 3,159 5,665 5,520

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Euro ‘000 31.12.2016 31.12.2015
     
Non-current assets    
Investment properties 141,740 86,810
Investment property under construction 1,580 -
Other non-current assets 288 263
Total non-current assets 143,608 87,073
     
Current assets    
Trade and other receivables 1,277 840
Prepayments 178 81
Cash and cash equivalents 9,883 1,677
Total current assets 11,338 2,598
Total assets 154,946 89,671
     
Equity    
Paid in capital 66,224 25,674
Cash flow hedge reserve (294) (199)
Retained earnings 10,887 6,218
Total equity 76,817 31,693
     
Non-current liabilities    
Interest bearing loans and borrowings 58,981 39,586
Deferred tax liabilities 4,383 3,673
Derivative financial instruments 345 215
Other non-current liabilities 935 451
Total non-current liabilities 64,644 43,925
     
Current liabilities    
Interest bearing loans and borrowings 10,191 11,608
Trade and other payables 2,876 2,036
Income tax payable 46 112
Derivative financial instruments - 17
Other current liabilities 372 280
Total current liabilities 13,485 14,053
Total liabilities 78,129 57,978
Total equity and liabilities 154,946 89,671

Additional information:

Tarmo Karotam Baltic Horizon Fund manager E-mail  tarmo.karotam@nh-cap.com www.baltichorizon.com

Distribution:  GlobeNewswire, Nasdaq Tallinn, Nasdaq Stockholm, www.baltichorizon.com

This announcement contains information that the Management Company is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above distributors, at 14.59 EET on 17 th  February 2017.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 10

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Microbot Medical Secures $13 Million in Recent Offering

Updated Category News Views 92

Microbot Medical Makes Strategic Move with $13 Million Offering Microbot Medical Inc. (NASDAQ: MBOT) has recently taken an important step to elevate its operations by entering into definitive agreements to sell 6,103,289 shares of its common stock at a price of $2.13 per share. This registered direct offering, priced at-the-market under Nasdaq rules, underscores the...

Continue Reading
Evolv Technologies Faces Class Action Lawsuit: Know Your Rights

Updated Category News Views 651

Understanding the Evolv Technologies Holdings Class Action Recent developments have raised significant concerns among shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). A class action lawsuit is currently in progress, prompting investors to scrutinize the implications of false statements made by the company. The allegations revolve around misleading...

Continue Reading
Rhino Rescue Unveils Innovative First Aid Kits for Adventurers

Updated Category News Views 117

Rhino Rescue Launches Innovative Products for Outdoor Safety Rhino Rescue has made a remarkable stride in enhancing outdoor safety with its new lineup of first aid kits targeted towards adventurers and everyday users alike. The release of the Rhino Rescue Mini First Aid Kit, along with home and camping-specific options, marks an exciting development in the company’s...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 258

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
BioSyent Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 132

BioSyent Inc. Announces Quarterly Dividend for Shareholders MISSISSAUGA, Ontario — BioSyent Inc. (TSX Venture: RX) is thrilled to communicate that its Board of Directors has approved a quarterly dividend of $0.05 per common share. This dividend will be paid in Canadian Dollars on a specified date to shareholders who are on record, enhancing the company's ongoing...

Continue Reading